TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04457427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuRx Diaphragm Pacing System (DPS)
Description: 4 electrodes are implanted into the diaphragm, 2 on each side, during the tracheostomy procedure. The electrodes are connected to the NeuRx external stimulator which will be used to stimulate and monitor diaphragm activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuRx Diaphragm Pacing System (DPS)
Description: 4 electrodes are implanted into the diaphragm, 2 on each side, during the tracheostomy procedure. The electrodes are connected to the NeuRx external stimulator which will be used to stimulate and monitor diaphragm activity.
Study: NCT01272999

Intervention type: OTHER
Intervention: No intervention
Description: Non interventional
Study: NCT04464161

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure
Description: Ensure protein is a complete nutritional drink with 10g, 240 calories, and 27 vitamins and minerals. It is often used as a nutritional supplementation in many hospitals.
Study: NCT04682080

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Needle-free injection
Description: This study was performed among children aged 4-10 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 120 patients were evaluated in accordance with the exclusion criteria and 94 children (39 girls and 55 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the colorful Wong-Baker Pain Scale at four time points: immediately after injection (Pain 1), during treatment (Pain 2), at the end of the treatment (Pain 3) and postoperative first day.Anxiety levels were recorded using the Modified Children's Dental Anxiety Scale face version

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Needle-free injection
Description: This study was performed among children aged 4-10 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 120 patients were evaluated in accordance with the exclusion criteria and 94 children (39 girls and 55 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the colorful Wong-Baker Pain Scale at four time points: immediately after injection (Pain 1), during treatment (Pain 2), at the end of the treatment (Pain 3) and postoperative first day.Anxiety levels were recorded using the Modified Children's Dental Anxiety Scale face version
Study: NCT03464500

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mitopure 500mg
Description: Mitopure containing softgels

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mitopure 1000mg
Description: Mitopure containing softgels

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo containing softgels
Study: NCT00646542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00589446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscope
Description: An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
Study: NCT04473456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous EGD and colonoscopy
Description: Patients are examined simultaneously by EGD and colonoscopy
Study: NCT03279380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNP
Description: Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training (HIIT)
Description: The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Continuous Training
Description: The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
Study: NCT01695473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
Study: NCT01148537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5, 10, 20, and 2 \* 20 mcg/h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo transdermal patch
Description: Placebo transdermal patch to match BTDS 5, 10, 20, and 2 \* 20.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelox (moxifloxacin hydrochloride) tablet
Description: Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
Study: NCT01784965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
Study: NCT02368717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine Enema

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Enema
Study: NCT01678183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Financial Incentive
Description: A cash payment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Financial Incentive
Description: A cash payment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Final Financial Incentive
Description: One-time payment in cash for each full percentage of hemoglobin A1c decrease over the eight-month period of the study.
Study: NCT03687216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVPG-guided therapy
Description: The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .~Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routing Therapy
Description: Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.
Study: NCT00874978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
Study: NCT01090401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linox smart S DX
Description: ICD lead
Study: NCT04044131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolic Cofactor Supplementation
Description: Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside. Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorbitol
Description: As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.
Study: NCT01405261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral NNC 0113-0987
Description: Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral NNC 0113-0987
Description: Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.v. NNC 0113-0987
Description: Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo
Description: Subjects will be randomised to receive a single dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo
Description: Subjects will be randomised to receive a single dose of placebo.
Study: NCT04001361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Cell Therapy
Description: Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Cell Therapy
Description: Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laser Cell Therapy
Description: Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
Study: NCT03685786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART19 cell and auto-HSCT
Description: Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T (CART19) Cells treatment for Adult Patient with Minimal Residual Disease(MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT). Subjects will receive 0.5-4 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 0, 10% fraction: 0.5-4x10\^7 CART19 cells, Day 1, 30% fraction: 1.5x10\^7-1.2x10\^8 CART19 cells, Day 2, 60% fraction: 3x10\^7-2.4x10\^8 CART19 cells. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
Study: NCT02072655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socio-aesthetic care
Description: * care of the face~* skin cleansing with cleansing milk to remove impurities~* a gentle scrub to exfoliate and cleanse the skin~* a relaxing massage~* moisturizing mask~* application of a moisturizer suited to specific patient skin: skin reactivity, dehydration ...~* care manicure / pedicure,~* massages~* makeup, advice (scarves, wigs care products adapted to the skin changes ...) and helping relationship.
Study: NCT02436707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Study: NCT01266863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E test method
Description: E test strips directly applied to BAL
Study: NCT03223064

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ferumoxtran-10 enhanced MRI; MRI contrast agent
Description: Patient undergo MRI with an USPIO contrast agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga PSMA PET-CT
Description: Patient undergo an 68Ga PSMA PET-CT scan
Study: NCT01687764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Treatment (ABMT) - Active
Description: The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Treatment (ABMT) - Active
Description: The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Treatment - Placebo
Description: The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attentional Bias Modification Treatment - Placebo
Description: The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy
Description: FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy
Description: FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Control Intervention
Description: Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducational Control Intervention
Description: Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
Study: NCT02277509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese DPP
Description: The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.~.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention Control
Description: Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
Study: NCT00919503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Infused IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Infused IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total body irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Single or double unit umbilical cord blood transplant, infused IV
Study: NCT04293861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYMOVIS
Description: HYMOVIS is a clear hydrogel obtained by hydration of the HA-based derivative named HYADD4p5. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process.
Study: NCT03725748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: irrigation
Description: irrigation the edges of the cs scar before closure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: irrigation
Description: irrigation the edges of the cs scar before closure
Study: NCT00160459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 5 mg Tablet, oral Daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10 mg Tablet, oral Daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25 mg Tablet, oral Daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral Daily for 12 weeks
Study: NCT03177772

Intervention type: BEHAVIORAL
Intervention: Pre-loss group therapy
Description: The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.

Intervention type: BEHAVIORAL
Intervention: Pre-loss group therapy
Description: The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.

Intervention type: BEHAVIORAL
Intervention: Pre-loss group therapy
Description: The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.
Study: NCT05097456

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide laser
Description: carbon dioxide laser

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham laser
Description: sham laser
Study: NCT03740256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAdVEC
Description: The intratumoral administration of CAdVEC will create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred HER2 specific CAR T cells via CAR (tumor antigen). We expect HER2 CAR T cells expanded at primary tumor sites will re-circulate and target metastasized tumors. The combination we propose to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cells. Testing each element separately would not be beneficial or informative, since the combination therapy is anticipated to have unique profiles of both therapeutic benefit and potential toxicities.